索托拉西布
| CAS号 | 2296729-00-3 | 货号 | BCP33368 |
| 中文名 | 索托拉西布 | ||
| 英文名 | Sotorasib | ||
| 中文别名 | 索托拉司;AMG-510单一构型;AMG510单一构型; | ||
| 英文别名 | AMG510;AMG 510;AMG-510; | ||
| 分子式 | C30H30F2N6O3 | 分子量 | 560.61 |
| 生物活性 | Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer. This mutation makes up >50% of all KRAS mutations. Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s. It is the first experimental KRAS inhibitor. The drug [MRTX849] is also currently being developed and has the same target. Sotorasib was granted FDA approval on May 28, 2021, followed by the European Commission's approval on January 10, 2022. | ||
| 上下游产品 | 2252403-56-6（AMG510 racemate(外消旋体)） | ||
| 信号通路 | GPCR/G Protein | ||
| 靶 点 | Ras/Rho | ||
结构式
本页面部分数据来自于公开的网络资源,所以瀚香生物不能保证其准确性。
不同批次的产品详情请咨询我们的客服：
- 全国免费电话：400-099-8200
- 在线客服:
瀚香生物（Biochempartner) 的所有产品和服务仅用于科学研究，禁止用于人体和治疗！